A major step towards developing a cure for cancer was taken during the week with a success recorded in the production of DNA-based vaccines by a United States company.
US-based Inovio Pharmaceuticals Inc announced, on Thursday, preliminary data showing that its INO-3112 DNA-based immunotherapy generated strong CD8+ T cell responses in three of four patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18. The data, which are T cell measurements from the first four treated patients of this phase I/IIa study, were on Thursday, presented at the World Vaccine Congress 2015 by Inovio’s Chief Operating Officer (COO), Dr. Niranjan Y. Sardesai.
Dr. J. Joseph Kim, Inovio’s President and Chief Executive Officer (CEO), said, “This initial data set from Inovio’s first cancer study provides encouraging evidence that we are on an important path to better optimised immunotherapy products. Regardless of whether it is an infectious disease, a precancer, or a cancer, the immune system uses the same mechanism to eliminate infected or mutated cells. In immune-oncology, it’s all about the T-cells. Here, we show in cancer patients that we can generate antigen-specific CD8+ killer T-cell responses, which are essential to an effective immunotherapy.
“We look forward to completing our currently enrolling studies for HPV-associated head and neck and cervical cancers, completing the preparations for our planned phase III study for cervical precancer, and launching new studies for hepatitis B and prostate cancer that all rely on the same targeted T-cell-based killing activity.”
This open-label study of HPV-caused head and neck cancer is intended to assess the safety, tolerability, and immunogenicity of up to 20 adults with HPV-positive head and neck squamous cell carcinoma. The study includes patients who are being treated with the drug before and after resection of their tumor as well as patients being treated with the drug after completion of chemotherapy and radiation therapy.
The company recently won a $45 million grant from the Defense Advanced Research Projects Agency (DARPA) to lead a collaborative team to develop products and a DNA-based vaccine against Ebola.
Inovio is the prime contractor on the DARPA program. Other collaborators are MedImmune, the global biologics R&D arm of AstraZeneca; GeneOne Life Sciences and its manufacturing subsidiary, VGLI; and Professor David B. Weiner, Ph.D., professor of pathology and laboratory medicine at UPenn, Emory and Vanderbilt.
Plans are to dose the first patient with Inovio’s vaccine during the second quarter of this year. In preclinical testing the vaccine protected 100 per cent of vaccinated animals from death and sickness after being exposed to a lethal dose of the Ebola virus.
“We are advancing against this virus on all fronts,” said Dr. Kim, in a statement thanking DARPA. The contract represents the largest single grant ever awarded to Inovio, which has previously won two grants totaling $28 million from the National Institutes of Health in 2015.
Fourteen years ago, Dr. Kim left a job developing vaccines for Merck to launch a new company with his former PhD. advisor. Today, Inovio is considered leader in the vaccine market for its drive to produce DNA vaccines: synthetic, gene-based medicines that train the body’s immune system to attack cancers, influenza, Ebola, even HIV/AIDS.
“In many ways, the immune system is like an iPhone without any software or apps,” he said. “By delivering small snippets of DNA that tell the immune system to recognise a cancer cell or flu virus as the enemy, we can more effectively train the immune system to destroy them.”
If his company is successful in bringing an Ebola and other DNA vaccines to market, it could change the way we think about disease—to say nothing of vaccines themselves. By attacking the disease at a DNA level, an Ebola vaccine could both prevent and treat the illness. Cancers could be cured or prevented with a single, risk-free shot. Public health crises ranging from flu season to Africa’s AIDS disaster could be brought under control. Fear-mongering over vaccines and their supposed side effects could be eased. And the financial rewards for Inovio and its investors—the value of the flu vaccine alone is estimated at $4 billion—could be astronomical.
Inovio is just one of several pharmaceutical companies chasing an Ebola vaccine, including Merck, Johnson & Johnson and GlaxoSmithKline. Though several ebola vaccines have been fast-tracked in the wake of the epidemic in West Africa, it’s still unclear when any will come to market.
Sources: CSBN and streetinsider.com
